T. Aurran‐Schleinitz

发表

Large B-cell lymphomas in adolescents and young adults in comparison to adult patients: a matched-control analysis in 55 patients

R. Bouabdallah, B. Chetaille, B. Esterni, 2014, Leukemia & lymphoma.

SHC and SHIP phosphorylation and interaction in response to activation of the FLT3 receptor

D. Birnbaum, O. Rosnet, J. Borg, 1999, Leukemia.

Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial

J. Gribben, L. Rassenti, T. Kipps, 2016, Blood Cancer Journal.

A role for HVEM, but not lymphotoxin‐β receptor, in LIGHT‐induced tumor cell death and chemokine production

D. Olive, A. Bernard, J. Rey, 2009, European journal of immunology.

Sarcoidosis Occurring After Solid Cancer: A Nonfortuitous Association

R. Bouabdallah, B. Chetaille, D. Coso, 2015, Medicine.

Peripheral T-cell lymphomas: analysis of histology, staging and response to treatment of 208 cases at a single institution

R. Bouabdallah, L. Xerri, B. Chetaille, 2013, Leukemia & lymphoma.

“One Hour” Rituximab Infusion Is Safe and Improves Patient Care and Outpatient Unit Management.

R. Bouabdallah, D. Coso, J. Rey, 2005 .

Management of central nervous system involvement in chronic lymphocytic leukaemia: a retrospective cohort of 30 patients

M. Boubaya, S. Leprêtre, X. Troussard, 2017, British journal of haematology.

Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study.

P. Feugier, S. Leprêtre, R. Letestu, 2017, The Lancet. Haematology.

Post-remission intervention with alemtuzumab or rituximab to eradicate minimal residual disease in chronic lymphocytic leukemia: where do we stand?

P. Feugier, S. Leprêtre, R. Letestu, 2012, Leukemia & lymphoma.

True histiocytic lymphoma following B‐acute lymphoblastic leukaemia: case report with evidence for a common clonal origin in both neoplasms

R. Bouabdallah, L. Xerri, B. Chetaille, 2001, British journal of haematology.

Identification of a new monoclonal B-cell subset in unaffected first-degree relatives in familial chronic lymphocytic leukemia

G. Marti, W. Telford, S. Perfetto, 2005, Leukemia.

Transplantation of allogeneic CD34+ blood cells in leukemia or lymphoma patients at high risk of GVHD

D. Blaise, C. Chabannon, F. Viret, 1999, Bone Marrow Transplantation.

Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia

Marc C. Jacob, M. Boubaya, J. Rossi, 2020, Leukemia.

Ibrutinib responsive central nervous system involvement in chronic lymphocytic leukemia.

V. Leblond, M. Hunault, Anne Wanquet, 2016, Blood.

Primary B-CLL Resistance to NK Cell Cytotoxicity can be Overcome In Vitro and In Vivo by Priming NK Cells and Monoclonal Antibody Therapy

R. Bouabdallah, D. Olive, D. Coso, 2012, Journal of Clinical Immunology.

Blood dendritic cells in patients with chronic lymphocytic leukaemia.

D. Olive, M. Mohty, B. Gaugler, 2008, Immunobiology.

Hepatitis B virus reactivation in HBsAg-negative patients is associated with emergence of viral strains with mutated HBsAg and reverse transcriptase.

D. Coso, F. Barlesi, C. Chabannon, 2015, Virology.

Bing-Neel syndrome, a rare complication of Waldenström macroglobulinemia: analysis of 44 cases and review of the literature. A study on behalf of the French Innovative Leukemia Organization (FILO).

S. Leprêtre, S. Kremer, L. Fornecker, 2015, Haematologica.

Bone marrow and blood cells as alternative sources of hematopoietic progenitors after failure of a first collection. A single institution retrospective study.

D. Blaise, P. Viens, C. Chabannon, 1996, Transplantation.

Prolymphocytic Leukemia: New Insights in Diagnosis and in Treatment

X. Troussard, E. Cornet, Anne Wanquet, 2017, Current Oncology Reports.

Characteristics of chronic lymphocytic leukemia patients achieving 5+ years of remission after FC‐based first‐line treatment: Retrospective observations from the FILO group

G. Salles, B. Pégourié, P. Feugier, 2018, American journal of hematology.

Salvage outcomes in patients with first relapse after fludarabine, cyclophosphamide, and rituximab for chronic lymphocytic leukemia: The French intergroup experience

P. Feugier, S. Leprêtre, L. Fornecker, 2015, American journal of hematology.

Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study.

Sun Ku Lee, M. Kersten, B. Cheson, 2019, The Lancet. Haematology.

Real‐world results of ibrutinib in relapsed/refractory CLL in France: Early results on a large series of 428 patients

P. Feugier, L. Ysebaert, P. Sinet, 2017, American journal of hematology.

Diagnosis and Treatment of Chronic Lymphocytic Leukemia: Recommendations of the French CLL Study Group (FILO)

P. Feugier, S. Leprêtre, R. Letestu, 2020, HemaSphere.

Bendamustine, Ofatumumab and High-Dose Methylprednisolone (BOMP) in Relapsed/Refractory CLL: Results of a Planned Interim Analysis of the French CLL Intergroup ICLL01 Phase II Trial

P. Feugier, S. Leprêtre, A. Schuh, 2014 .

Psychological Outcomes and Quality of Life in Relation to Pancreatectomy: A Systematic Review

J. Delpero, O. Turrini, V. Bréjard, 2019, Pancreas.

Early progenitor cells from human mobilized peripheral blood express low levels of the flt3 receptor, but exhibit various biological responses to flt3‐L

C. Chabannon, L. Humeau, P. Charbord, 1999, British journal of haematology.

First‐line treatment of double‐hit and triple‐hit lymphomas: Survival and tolerance data from a retrospective multicenter French study

P. Coppo, F. Morschhauser, E. Gyan, 2020, American journal of hematology.

Efficacy and safety of lenalinomide combined with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma

R. Bouabdallah, B. Chetaille, B. Esterni, 2014, Leukemia & lymphoma.

Blinatumomab for Patients with Richter Syndrome: Final Results of the Phase 2 Blinart Trial from the Filo Group

P. Feugier, B. Drénou, L. Fornecker, 2022, Blood.

A phase II study of lenalidomide and rituximab (R2) combination in patients with high-risk refractory/relapsed diffuse large B-cell lymphoma.

R. Bouabdallah, D. Coso, N. Vey, 2023, Hematology.